Skip to main content
Orchid Pharma Limited logo

Orchid Pharma Limited — Investor Relations & Filings

Ticker · ORCHPHARMA ISIN · INE191A01027 LEI · 33580076KIKCYSLZVF05 BSE.NS Manufacturing
Open in API
Filings indexed 448 across all filing types
Latest filing 2026-05-14 Regulatory Filings
Country IN India
Listing BSE.NS ORCHPHARMA

About Orchid Pharma Limited

https://www.orchidpharma.com/

Orchid Pharma Limited is a vertically integrated organization focused on the development, manufacture, and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company specializes in the anti-infectives segment, with a particular emphasis on cephalosporins and penicillins. Its operations span the entire value chain, including advanced research and development, process chemistry, and large-scale manufacturing. Orchid Pharma maintains facilities that adhere to rigorous international regulatory standards, enabling the supply of high-quality generic formulations and complex molecules to global markets. The company prioritizes innovation in chemical synthesis and formulation development to address complex therapeutic requirements and enhance healthcare outcomes through a robust portfolio of essential medicines.

Recent filings

Filing Released Lang Actions
Monitoring Agency Report for the Quarter- IV of financial year 2025-26 ended March 31, 2026.
Regulatory Filings Classification · 83% confidence The document is a formal disclosure to stock exchanges under SEBI Listing Regulations, enclosing the Monitoring Agency Report for Q4 ended March 31, 2026, in respect of utilization of QIP proceeds. It is not a standalone financial report (e.g., 10-K or interim report), nor an earnings release or management discussion. Rather, it is a compliance/regulatory filing required under SEBI regulations. Therefore, it best fits the catch-all category “Regulatory Filings (RNS).”
2026-05-14 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a declaration regarding encumbrance of shares of Orchid Pharma Limited for the financial year 2025-26, submitted by Dhanuka Laboratories Limited, the promoter. It references Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011. The content is a formal declaration about share encumbrance status, not a financial report, audit, or management discussion. It is a regulatory compliance filing related to shareholding disclosures but does not fit into major shareholding notification (MRQ) since it declares no change in encumbrance. The document is short (2175 characters) and is a formal regulatory declaration. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2026-05-05 English
Action(s) taken or orders passed
Regulatory Filings Classification · 95% confidence The document is an official intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements, 2015. It informs about a legal order from the National Company Law Tribunal dismissing an application by DBS Bank related to lease rent claims during the Corporate Insolvency Resolution Process (CIRP) period. The document includes details of the order and the legal proceedings but does not contain financial statements or detailed financial analysis. It is a regulatory announcement about a legal proceeding outcome, not a full legal proceedings report or a financial report. Given the nature of the content and the regulatory context, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-11 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-09 English
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing about an upcoming Investor Roadshow scheduled for April 10, 2026. It is a notification about a planned event involving company management meeting investors. The document explicitly states that no unpublished price sensitive information will be shared. There is no financial data, report, or detailed presentation included. The document is short (1878 characters) and serves as an announcement of an event rather than a report or detailed investor presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-07 English
Credit Rating- Revision
Regulatory Filings
2026-04-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.